Comparison of the AdvanSure Human Papillomavirus Screening Real-Time PCR, the Abbott RealTime High Risk Human Papillomavirus Test, and the Hybrid Capture Human Papillomavirus DNA Test for the Detection of Human Papillomavirus
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: We evaluated the performance of various commercial assays for the molecular detection of human papillomavirus (HPV); the recently developed AdvanSure HPV Screening real-time PCR assay (AdvanSure PCR) and the Abbott RealTime High Risk HPV PCR assay (Abbott PCR) were compared with the Hybrid Capture 2 HPV DNA Test (HC2). Methods: All 3 tests were performed on 177 samples, and any sample that showed a discrepancy in any of the 3 tests was genotyped using INNO-LiPA HPV genotyping and/or sequencing. On the basis of these results, we obtained a consensus HPV result, and the performance of each test was evaluated. We also evaluated high-risk HPV 16/18 detection by using the 2 real-time PCR assays. Results: Among the 177 samples, 65 were negative and 75 were positive in all 3 assays; however, the results of the 3 assays with 37 samples were discrepant. Compared with the consensus HPV result, the sensitivities and specificities of HC2, AdvanSure PCR, and Abbott PCR were 97.6%, 91.7%, and 86.9% and 83.9%, 98.8%, and 100.0%, respectively. For HPV type 16/18 detection, the concordance rate between the AdvanSure PCR and Abbott PCR assays was 98.3%; however, 3 samples were discrepant (positive in AdvanSure PCR and negative in Abbott PCR) and were confirmed as HPV type 16 by INNO-LiPA genotyping and/or sequencing. Conclusions: For HPV detection, the AdvanSure HPV Screening real-time PCR assay and the Abbott PCR assay are less sensitive but more specific than the HC2 assay, but can simultaneously differentiate type 16/18 HPV from other types.
Abstract
Background: We evaluated the performance of various commercial assays for the molecular detection of human papillomavirus (HPV); the recently developed AdvanSure HPV Screening real-time PCR assay (AdvanSure PCR) and the Abbott RealTime High Risk HPV PCR assay (Abbott PCR) were compared with the Hybrid Capture 2 HPV DNA Test (HC2). Methods: All 3 tests were performed on 177 samples, and any sample that showed a discrepancy in any of the 3 tests was genotyped using INNO-LiPA HPV genotyping and/or sequencing. On the basis of these results, we obtained a consensus HPV result, and the performance of each test was evaluated. We also evaluated high-risk HPV 16/18 detection by using the 2 real-time PCR assays. Results: Among the 177 samples, 65 were negative and 75 were positive in all 3 assays; however, the results of the 3 assays with 37 samples were discrepant. Compared with the consensus HPV result, the sensitivities and specificities of HC2, AdvanSure PCR, and Abbott PCR were 97.6%, 91.7%, and 86.9% and 83.9%, 98.8%, and 100.0%, respectively. For HPV type 16/18 detection, the concordance rate between the AdvanSure PCR and Abbott PCR assays was 98.3%; however, 3 samples were discrepant (positive in AdvanSure PCR and negative in Abbott PCR) and were confirmed as HPV type 16 by INNO-LiPA genotyping and/or sequencing. Conclusions: For HPV detection, the AdvanSure HPV Screening real-time PCR assay and the Abbott PCR assay are less sensitive but more specific than the HC2 assay, but can simultaneously differentiate type 16/18 HPV from other types.
참고문헌 (16)
- Franco EL, "Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination", Vaccine, 24(S3), pp.171~177 (2006)
- Meijer CJ, "Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older", Int J Cancer, 124, pp.516~520 (2009)
- Poljak M, "Commercially available assays for multiplex detection of alpha human papillomaviruses", Expert Rev Anti Infect Ther, 8, pp.1139~1162 (2010)
- Mo LZ, "Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results", J Clin Virol, 41, pp.104~110 (2008)
- Cuzick J, "Overview of the European and North American studies on HPV testing in primary cervical cancer screening", Int J Cancer, 119, pp.1095~1101 (2006)
- Koliopoulos G, "Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies", Gynecol Oncol, 104, pp.232~246 (2007)
- Arbyn M, "How to evaluate emerging technologies in cervical cancer screening?", Int J Cancer, 125, pp.2489~2496 (2009)
- Seme K, "Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping", J Virol Methods, 134, pp.252~256 (2006)
- Castle PE, "Human papillomavirus genotype specificity of hybrid capture 2", J Clin Microbiol, 46, pp.2595~2604 (2008)
- Schutzbank TE, "Detection of high-risk papillomavirus DNA with commercial invadertechnology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media", J Clin Microbiol, 45, pp.4067~4069 (2007)
- Eder PS, "The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform", J Clin Virol, 45(S1), pp.S85~S92 (2009)
- "Instructor’s insert of AdvanSure HPV Screening real-time PCR" (2010), LG Life Science
- Halfon P, "Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection", J Clin Virol, 48, pp.246~250 (2010)
- Huang S, "Principles and analytical performance of Abbott RealTime High Risk HPV test", J Clin Virol, 45(S1), pp.S13~S17 (2009)
- Poljak M, "The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test", Acta Dermatovenerol Alp Panonica Adriat, 18, pp.94~103 (2009)
- "Instructor’s insert of Abbott RealTime High Risk HPV" (2010), Abbott molecular